Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Bellecapital International Ltd.

Share on StockTwits

Bellecapital International Ltd. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,598 shares of the biopharmaceutical company’s stock after purchasing an additional 585 shares during the quarter. Bellecapital International Ltd.’s holdings in Gilead Sciences were worth $784,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV lifted its stake in shares of Gilead Sciences by 55.9% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 165 shares during the period. Trustcore Financial Services LLC purchased a new position in shares of Gilead Sciences in the 1st quarter valued at approximately $34,000. Weaver Consulting Group bought a new position in Gilead Sciences during the 1st quarter valued at approximately $34,000. Legacy Advisors LLC bought a new position in Gilead Sciences during the 2nd quarter valued at approximately $37,000. Finally, Founders Capital Management increased its position in Gilead Sciences by 50.0% during the 1st quarter. Founders Capital Management now owns 600 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 78.87% of the company’s stock.

NASDAQ:GILD opened at $62.87 on Friday. The business’s 50-day moving average is $66.24 and its 200 day moving average is $65.91. The company has a current ratio of 3.76, a quick ratio of 3.67 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61. The company has a market capitalization of $81.03 billion, a P/E ratio of 10.22, a P/E/G ratio of 3.04 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $1.68 by $0.14. The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.54 billion. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The company’s quarterly revenue was down 2.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.91 earnings per share. On average, research analysts forecast that Gilead Sciences, Inc. will post 6.65 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, September 12th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.01%. Gilead Sciences’s dividend payout ratio is 40.98%.

A number of research analysts recently weighed in on GILD shares. BMO Capital Markets set a $82.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, July 31st. Evercore ISI reissued a “buy” rating on shares of Gilead Sciences in a report on Friday, May 17th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $85.00 target price on shares of Gilead Sciences in a report on Wednesday, July 31st. Cantor Fitzgerald set a $88.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Monday, July 15th. Finally, Zacks Investment Research lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, May 2nd. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $82.29.

In related news, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total value of $468,504.00. Following the completion of the sale, the executive vice president now owns 34,398 shares in the company, valued at $2,238,277.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 5,816 shares of the company’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total value of $399,850.00. Following the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Market Timing

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.